Q1 Earnings Estimate for BioNTech Issued By Leerink Partnrs

BioNTech SE (NASDAQ:BNTX) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for BioNTech in a research report issued to clients and investors on Monday, April 21st. Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings per share of ($5.78) for the quarter. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. Leerink Partnrs also issued estimates for BioNTech’s Q2 2025 earnings at ($2.70) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at $0.07 EPS, FY2025 earnings at ($9.20) EPS, FY2026 earnings at ($3.87) EPS, FY2027 earnings at ($2.62) EPS, FY2028 earnings at ($1.79) EPS and FY2029 earnings at ($0.63) EPS.

Other equities analysts also recently issued research reports about the company. Morgan Stanley cut their price target on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Canaccord Genuity Group reissued a “buy” rating and issued a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Truist Financial began coverage on shares of BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective on the stock. BMO Capital Markets increased their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Finally, HC Wainwright cut their price target on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $143.44.

BioNTech Price Performance

Shares of BNTX opened at $114.97 on Wednesday. The business’s fifty day moving average is $102.13 and its 200 day moving average is $110.78. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a market cap of $27.59 billion, a P/E ratio of -54.75 and a beta of 1.07.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter last year, the firm earned $1.90 earnings per share. BioNTech’s quarterly revenue was down 19.5% on a year-over-year basis.

Institutional Trading of BioNTech

Several institutional investors and hedge funds have recently made changes to their positions in BNTX. Jones Financial Companies Lllp raised its stake in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after acquiring an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. raised its position in BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE purchased a new stake in shares of BioNTech in the 4th quarter worth $90,000. GAMMA Investing LLC grew its position in shares of BioNTech by 48.2% during the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after buying an additional 300 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new position in shares of BioNTech during the fourth quarter valued at $137,000. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.